Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells <i>In vivo</i> and <i>In vitro</i> Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis
Clinical cancer research